Bioactive nanotherapeutic trends to combat triple negative breast cancer

The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, and sacituzumab can tackle the breast cancer prognosis and/or progression, but achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdhury, Pallabita, Ghosh, Upasana, Samanta, Kamalika, Jaggi, Meena, Chauhan, Subhash C., Yallapu, Murali M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970221/
https://www.ncbi.nlm.nih.gov/pubmed/33778204
http://dx.doi.org/10.1016/j.bioactmat.2021.02.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970221/
https://www.ncbi.nlm.nih.gov/pubmed/33778204
http://dx.doi.org/10.1016/j.bioactmat.2021.02.037

Ejemplares similares